Deregulation of innate and adaptive immune responses in human papillomavirus infection and cancer |
|
Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 |
|
The human T cell receptor repertoire : evidence for non-random sequential development of the αβTCR repertoire and peptide driven selection of TCR β chain sequences |
|
Identification and evaluation of cytotoxic T-cell epitopes in HIV-1 and tumour-associated proteins |
|
Identification of human minor histocompatibility antigens |
|
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine |
|
Immunotherapy of established |
|
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors |
|
Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy |
|
In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway |
|
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer |
|
Inflammasome-Dependent Induction of Adaptive NK Cell Memory. |
|
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. |
|
Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. |
|
Leukocytenantistoffen en immuun adherentie |
|
Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. |
|
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody |
|
Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment |
|
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study |
|
Macrophages are vital in spontaneous intraocular tumor eradication |
|
Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. |
|
Maintenance of immune tolerance depends on normal tissue homeostasis |
|
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. |
|
Migration or evasion |
|
Mini‐review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross‐priming and direct priming? |
|
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists |
|
N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. |
|
Naturally processed peptides presented by MHC class I following measles virus infection |
|
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy |
|
New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. |
|
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways |
|
Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance |
|
Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication |
|
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. |
|
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. |
|
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. |
|
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity |
|
Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer |
|
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization |
|
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer |
|
Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. |
|
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention |
|
Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10—producing CD4+ T cells |
|
Recruitment of cellular immune responses in the fight against cancer : towards application of tissue-specific cytotoxic T lymphocytes |
|
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition |
|
Revival of the regulatory T cell: new targets for drug development |
|
Safety in numbers |
|
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients |
|
Scientific contributions toward successful cancer immunotherapy in The Netherlands. |
|
Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies |
|
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants |
|
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen |
|
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. |
|
Skin-Depigmenting Agent Monobenzone Induces Potent T-Cell Autoimmunity toward Pigmented Cells by Tyrosinase Haptenation and Melanosome Autophagy |
|
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia |
|
Smart delivery of vaccines |
|
SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity |
|
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells |
|
The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development |
|
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival |
|
Structured reporting of T cell assay results |
|
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses |
|
Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy |
|
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation |
|
Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. |
|
Synthetic vaccines, 2012: |
|
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. |
|
T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy |
|
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
|
Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. |
|
Therapeutic vaccination against human papilloma virus induced malignancies |
|
TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients |
|
Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine |
|
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. |
|
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. |
|
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma |
|
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy |
|
The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. |
|
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. |
|
Vaccination for treatment and prevention of cancer in animal models. |
|
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. |
|
Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death |
|
Vaccines for established cancer: overcoming the challenges posed by immune evasion |
|
The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. |
|